echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Hormone replacement therapy increases the risk of breast leaf cancer in 3 years

    Hormone replacement therapy increases the risk of breast leaf cancer in 3 years

    • Last Update: 2020-07-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    report from the Fred Hutchinson Cancer Research Center in Seattle, USA, that the combination of estrogen and progesterone (CHT) after menopause significantly increases the risk of breast leaf cancer in just three years(Cancer Epideol Biomarkers Prev 2008, 17 (1): 43)previous studies have suggested that CHT applications for at least five years can lead to an increased risk of breast cancer, so what about shortening the application time? To do this, the researchers conducted a population case-control studyThe study included 324 cases of breast leaf cancer, 196 cases of breast catheter-small leaf hybrid cancer and 524 cases of breast catheterized cancer, as well as 469 population controls, diagnosed in 2000-2004Tissue samples from 83% of patients were tested by the central laboratoryThe correlation between hormone use and breast cancer risk was evaluated by the logistic regression method of multi-classification ordered reaction variableThe results showed that in patients with CHT for 3 years and currently being applied, the risk of breast lobe cancer and breast catheter small leaf cancer increased by 2.7 and 3.3 times, respectively, and was not related to thestaging, size and lymph node condition oftumorIn patients with breast catheter small leaf hybrid cancer, CHT can cause an increase in the risk of small leaf-based cancer (RATIO (OR) s 4.8, 95% confidence interval (CI) 2.1 to 11.1), but does not increase the risk of catheter-based cancer (OR.9,95% CI 0.9 to 4.1)At present, the risk of breast catheter cancer in people who applied CHT increased by 1.4 times, but there was no statisticalsignificanceThe researchers believe that the findings will not fundamentally change current hormone therapy recommendations, and that patients in need can still be applied, but should be used as slowly as possible and the dose should be as small as possible
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.